Page last updated: 2024-10-25

debrisoquin and Epilepsy

debrisoquin has been researched along with Epilepsy in 1 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spina, E1
Avenoso, A1
Campo, GM1
Caputi, AP1
Perucca, E1

Trials

1 trial available for debrisoquin and Epilepsy

ArticleYear
Phenobarbital induces the 2-hydroxylation of desipramine.
    Therapeutic drug monitoring, 1996, Volume: 18, Issue:1

    Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450

1996